更新于：2024-11-01
Trimethoprim
甲氧苄啶
更新于：2024-11-01
概要
基本信息
药物类型 小分子化药 |
别名 TMP、Trimethoprim (JAN/USP/INN)、BW-56-72 + [7] |
作用机制 Bacterial DHFR抑制剂(细菌二氢叶酸还原酶抑制剂) |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 美国 (1980-05-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C14H18N4O3 |
InChIKeyIEDVJHCEMCRBQM-UHFFFAOYSA-N |
CAS号738-70-5 |
关联
30
项与 甲氧苄啶 相关的临床试验A Phase II, Open Label, Randomized Controlled Pilot Study Evaluating Trimethoprim in Patients Commencing Androgen Deprivation Therapy for Prostate Cancer
A study on the effect of trimethoprim plus thioglycollate gel filling for the prevention of postoperative stricture in large esophageal ESD
Retentive Strength of Various Dental Adhesives on Various Types of Residual Ridged
100 项与 甲氧苄啶 相关的临床结果
登录后查看更多信息
100 项与 甲氧苄啶 相关的转化医学
登录后查看更多信息
100 项与 甲氧苄啶 相关的专利（医药）
登录后查看更多信息
15,111
项与 甲氧苄啶 相关的文献（医药）2025-01-01FOOD CHEMISTRY
Extraction of phenolic acids and tetramethylpyrazine in Shanxi aged vinegar base on vortex-assisted liquid-liquid microextraction-hydrophobic deep eutectic solvent: COSMO-RS calculations and ANN-GA optimization
Article
作者: Zhang, Ziqing ; Bai, Baoqing ; Bo, Tao ; Zhang, Jinhua ; Meng, Siyuan ; Chen, Rui ; Yang, Yukun ; Fan, Sanhong ; Guo, Yanli
In this study, vortex-assisted liquid-liquid microextraction (VA-LLME) based on hydrophobic deep eutectic solvents (HDES) was used to efficiently and sustainably extract five phenolic acids and tetramethylpyrazine (TMP) from Shanxi aged vinegar (SAV). The VA-LLME technique was employed to investigate the extraction mechanism of HDES with the best extraction performance for the target compounds using a conductor-like screening model for real solvents (COSMO-RS). An artificial neural network combined with a genetic algorithm (ANN-GA) was developed to optimize the extraction conditions based on single-factor and response surface methodology, while also analyzing the interactive effects on the phenolic acids and TMP in the extracted solution during the extraction phase. The optimized conditions were determined, and the greenness of the procedure was evaluated using an analytical greenness metric, indicating that this technique can serve as a green alternative for the determination of phenolic acids and TMP in SAV.
2025-01-01WATER RESEARCH
Combined ozonation-biological activated carbon process for antibiotic resistance control in treated effluent from wastewater treatment plant
Article
作者: Xue, Xi ; Hu, Jiangyong ; Zhang, Xinyang
Biological activated carbon (BAC) treatment plays a crucial role in wastewater treatment plants due to its economic and effective promotion of organic matter degradation or mineralization. However, whether the changes in antibiotic resistance (AR) resulting from BAC or O3-BAC treatment are related to environmental factors remains unclear, as previous studies have primarily focused on isolated aspects, or have combined these aspects without systematically comparing the BAC and O3-BAC treatment processes or analyzing their interrelationships. In this study, to gain a clearer understanding of the factors related to AR during the BAC treatment, the treatment process of BAC and O3-BAC were comprehensively compared, including antibiotics removal, wastewater matrix changes, antibiotic resistant bacteria (ARB), antibiotic resistance genes (ARGs), and bacterial community characteristics. The roles of O3 pretreatment and the bed depth of BAC were also clarified. ARGs were found to be not as sensitive to ozone as ARB. In addition, further strengthening of control measures should be needed for trimethoprim and tetracycline, due to their low removal efficiencies by ozone pretreatment, and their close relationship with the increased AR. Besides, 2 mg/L ozonation pretreatment could significantly influence the microbial community composition of wastewater and biofilm samples, while 1 mg/L ozonation could not. Finally, the correlation of environmental factors, bacterial communities, and ARGs revealed that to reduce the AR risks of O3-BAC treatment, antibiotics in wastewater should be strictly controlled, since they were positively correlated with the accumulation of ARGs and Pseudomonadota, Actinomycetota, and Bacteroidota, which were responsible for carrying and disseminating ARGs. The results showed that higher dose ozonation pre-treatment and longer bed depth of BAC process could help control the AR of BAC.
2025-01-01The Journal of Pediatrics
Prenatal and Postnatal Exposure to Antibiotics and the Risk of Type 1 Diabetes in Finnish Children: A Registry-based Study
Article
作者: Gissler, Mika ; Lundqvist, Annamari ; Metsälä, Johanna ; Virtanen, Suvi M ; Hakola, Leena ; Virta, Lauri J
OBJECTIVE:
To study whether prenatal and postnatal exposure to antibiotics is associated with the risk of type 1 diabetes in childhood.
STUDY DESIGN:
This case cohort study included 2869 children diagnosed with type 1 diabetes by the end of 2009 who were born between January 1, 1996, and December 31, 2008, in Finland and a reference cohort (n = 74 263) representing 10% of each birth cohort. Exposure to antibiotics was assessed in different time periods. The data were derived from Special Reimbursement Register, Drug Prescription Register, and Population Register and analyzed with weighted Cox proportional hazards regression models.
RESULTS:
Exposure to any antibiotics before or during pregnancy, in the neonatal ward, during the first year of life, or during the 2 first years of life, was not associated with the risk of type 1 diabetes in the offspring. Exposure to macrolides in the year preceding pregnancy (adjusted hazard ratio [HR], 1.17; 95% CI, 1.02-1.33) and to sulfonamides and trimethoprim during pregnancy (adjusted HR, 1.91; 95% CI, 1.07-3.41) was associated with an increased risk of type 1 diabetes in the offspring. Exposure to sulfonamides and trimethoprim during first 2 years of life was associated with a decreased risk of type 1 diabetes (adjusted HR, 0.84; 95% CI, 0.73-0.97). The number of antibiotic purchases among mothers or children was not associated with type 1 diabetes risk.
CONCLUSIONS:
Prenatal and postnatal exposure to antibiotics in general did not increase the risk of type 1 diabetes in the offspring. However, the type of antibiotic and timing of exposure may play a role in type 1 diabetes risk.
100 项与 甲氧苄啶 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 泌尿道感染 | 澳大利亚 | 1991-08-02 | |
| 细菌感染 | 美国 | 1980-05-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 92 | (Patients With Recurrent UTIs Arm 1) | 鹽構鬱簾積醖鑰願顧糧(蓋鏇構鑰醖襯繭齋簾積) = 鏇鏇鹽繭夢願鬱網鹹壓 簾淵襯獵醖醖夢壓餘襯 (繭顧鏇衊簾衊繭憲網製, 觸網夢醖淵憲製築觸醖 ~ 膚齋鏇積網鹹襯餘構齋) 更多 | - | 2020-01-14 | ||
(Patients With Recurrent UTIs Arm 2) | 鹽構鬱簾積醖鑰願顧糧(蓋鏇構鑰醖襯繭齋簾積) = 淵構鹽鬱選廠顧壓簾鑰 簾淵襯獵醖醖夢壓餘襯 (繭顧鏇衊簾衊繭憲網製, 艱範艱簾夢鏇糧遞鬱壓 ~ 遞鬱遞齋襯壓願鹹艱願) 更多 | ||||||
N/A | 慢性肾病 creatinine | 20 | 壓選顧廠鏇窪製膚獵窪(夢簾積製積選窪顧憲憲) = 衊淵糧顧鏇範積顧遞淵 築醖獵選築鏇繭廠顧襯 (餘遞襯願繭顧選構顧醖 ) | 积极 | 2019-06-13 | ||
N/A | 48 | High dose TMP-SMX | 願憲憲齋壓製獵鑰憲窪(壓鏇憲廠膚範顧膚艱願) = 廠壓遞簾築選繭範醖鹹 醖憲憲製齋選餘顧廠鑰 (構鏇簾顧製廠糧襯網網 ) | 积极 | 2014-11-11 | ||
N/A | - | - | 醖獵積遞遞艱艱鑰餘淵(壓夢廠選艱築繭構願艱) = 淵糧獵鬱膚觸鏇艱襯範 鏇糧餘糧憲鹽窪餘淵衊 (遞襯築鬱襯選繭遞壓醖 ) 更多 | - | 2013-11-01 | ||
鏇鹽壓製範構壓簾糧糧(淵齋網糧繭淵衊構選範) = 廠鏇鑰獵鏇觸淵餘築醖 獵選獵簾構築範齋淵鑰 (憲積繭醖積蓋網範壓衊 ) 更多 | |||||||
N/A | 系统性红斑狼疮 anti-Ro/SS-A antibody | 31 | TMP/SMX | 願獵繭齋構餘憲鏇衊淵(夢蓋窪顧壓膚淵鹽艱鏇) = 願鹹鏇衊鹽選蓋獵鏇糧 範夢淵鹹糧範觸願糧顧 (觸夢顧鑰憲選襯鹹鹹鏇 ) | 积极 | 2013-02-01 | |
临床2期 | 36 | Islet Transplantation+Ganciclovir+Sulfamethoxazole+Tacrolimus+Sirolimus+Daclizumab+Pentamidine+Trimethoprim | 顧願廠繭廠網繭鏇壓鹹(憲齋鑰醖製獵襯艱鑰鬱) = 膚窪餘網衊鹽餘蓋築範 網糧獵鹹製壓壓齋鬱選 (廠觸鏇蓋鏇窪簾糧網簾, 憲糧襯膚廠築窪顧膚艱 ~ 鏇衊衊醖選鏇膚憲獵遞) 更多 | - | 2012-10-17 | ||
N/A | 6 | Sulfa | 選廠窪鏇醖憲製遞網鹹(繭窪願製遞夢鏇憲壓窪) = 5/6 developed cutaneous burning sensation followed by generalized maculopapular rash with a median onset after the last dose of 12 hours. Only antihistamines were used. The symptoms resolved within 6 days (median of 2 days, range 1-6 days) 製製鬱壓醖壓積範廠鹹 (壓膚夢構鏇積選鹹齋齋 ) | - | 2007-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用